Key result
CCR2 Val64Ile polymorphism is not linked to coronary events in men with raised cholesterol.
Why the study?
Several lines of evidence support a role for CCL2 and its receptor CCR2 in atherosclerosis, but the association of the CCR2 Val64Ile polymorphism with coronary artery disease was unclear.
Is the CCR2 Val64Ile polymorphism associated with the development of coronary artery disease?
Case-Control (n=1,446)
Is the CCR2 Val64Ile polymorphism associated with the development of coronary artery disease?
The CCR2 Val64Ile polymorphism does not appear to have a significant association with or protective role against the development of coronary artery disease.
Answers are grounded in this paper and cite their sources.
No association found in this case-control study; leaves open any role for CCR2 Val64Ile in CAD risk and should not change practice.
BACKGROUND: Several lines of evidence support a role for CCL2 (monocyte chemotactic protein-1) and its receptor CCR2 in the development of atherosclerosis. The aim of the present study was to determine the association of the CCR2 Val64Ile polymorphism with the development of coronary artery disease in the WOSCOPS study sample set. FINDINGS: A total of 443 cases and 1003 controls from the West of Scotland Coronary Prevention Study (WOSCOPS) were genotyped for the Val64Ile polymorphism in the CCR2 gene. Genotype frequencies were compared between cases and controls. The CCR2 Val64Ile polymorphism was found not to be associated with coronary events in this study population (odds ratio 1.15, 95% CI 0.82-1.61, p = 0.41). CONCLUSIONS: This case-control study does not support an association of the CCR2 Val64Ile polymorphism with coronary artery disease in the WOSCOPS sample set and does not confirm a possible protective role for CCR2 Val64Ile in the development of coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Dow et al. (2010) conducted a case-control in Coronary artery disease (n=1,446). CCR2 Val64Ile polymorphism vs. Val/Val genotype was evaluated on Death from definite coronary artery disease, non-fatal acute myocardial infarction, or re-vascularisation (OR 1.15, 95% CI 0.82-1.61, p=0.41). The CCR2 Val64Ile polymorphism was not associated with the development of coronary events in men with raised cholesterol.
Synapse has enriched 10 related papers. Consider them for comparative context: